

**Table E-3. Study characteristics for trials comparing other prescriptions with placebo**

<b>Study</b>	<b>Country</b>	<b>Sites</b>	<b>Analyzed</b>	<b>Design</b>	<b>Study Arms</b>	<b>F/U (weeks)</b>	<b>Industry Funding</b>	<b>Editorial Assistance</b>
Clayden 1974	United Kingdom	18	85	Crossover	2	4		No/NR
Guttuso 2003	United States	1	59	RCT Plac Compare	2	12		No/NR
Butt 2008	Canada	NR	197	RCT Plac Compare	2	4	Yes	No/NR
Joffe 2010	United States	NR	59	Crossover	2	4	Yes	No/NR
Depomed (c) 2012	United States	45	532	RCT Plac Compare	3	12	Yes	No/NR
Depomed (c) 2012	United States	45	559	RCT Plac Compare	3	12	Yes	No/NR
Pinkerton 2013	United States	67	593	RCT Plac Compare	2	24	Yes	No/NR

(c): data came from posted results on the clinical trial registry; F/U: followup; NR: not reported; Plac: placebo; RCT: randomized controlled trial;